CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed refractory solid tumor and/or lymphoma
• •No brain metastases or primary CNS malignancies
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •More than 3 months
• •Hematopoietic:
• •Granulocyte count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hepatic:
• •Bilirubin normal
• •ALT and AST less than 2.5 times normal
• •Renal:
• •Creatinine no greater than 1.5 mg/dL OR
• •Creatinine clearance greater than 60 mL/min
• •Cardiovascular:
• •No unstable or newly diagnosed angina pectoris
• •No myocardial infarction within the past 6 months
• •No New York Heart Association class II, III, or IV congestive heart failure
• •Pulmonary:
• •No chronic obstructive lung disease requiring oxygen therapy
• •Other:
• •No uncontrolled seizures
• •No concurrent acute critical illness
• •No serious untreated infection
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 2 months after study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 4 weeks since prior biologic therapy
• •Chemotherapy:
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or carboplatin)
• •No concurrent cytotoxic chemotherapy
• •Endocrine therapy:
• •At least 4 weeks since prior hormonal therapy
• •Concurrent luteinizing hormone-releasing hormone agonist required in patients with prostate cancer unless prior orchiectomy has been performed
• •Radiotherapy:
• •At least 4 weeks since prior radiotherapy
• •Surgery:
• •See Endocrine therapy
• •Prior surgery allowed
• •Other:
• •Recovered from prior therapy
• •No concurrent anticonvulsants (e.g., phenobarbital, phenytoin, or carbamazepine)
• •No concurrent rifampin
• •No concurrent grapefruit juice